BiotechTubeBiotechTube
Home/Pipeline/HS-10342

HS-10342

Advanced Solid Tumors

Phase 1/2Active

Key Facts

Indication
Advanced Solid Tumors
Phase
Phase 1/2
Status
Active
Company
Hansoh Pharma

About Hansoh Pharma

Hansoh Pharmaceutical Group is one of China's premier pharmaceutical companies, specializing in innovative drug development across oncology, central nervous system disorders, and other therapeutic areas. Founded in 1995, the company has successfully commercialized multiple products in China and is expanding its pipeline with novel small molecules and biologics. Hansoh went public on the Hong Kong Stock Exchange in 2019 and continues to invest heavily in R&D to develop first-in-class and best-in-class therapies.

View full company profile

Therapeutic Areas

OncologyCentral Nervous SystemImmunologyBiosimilars

Other Advanced Solid Tumors Drugs

DrugCompanyPhase
SHR-1701Jiangsu Hengrui MedicinePhase 1
BAY 1895344BayerPhase 1
ANKTIVA® + M-ceNKImmunityBioPhase 1
DFTX-101Definium TherapeuticsPhase 1/2
REC-617Recursion PharmaceuticalsPhase 1/2
ZW220ZymeworksPreclinical
NX-1607Nurix TherapeuticsPhase 1a
IMA402 (TCR Bispecific)ImmaticsPhase 1
IMA403 (TCR Bispecific)ImmaticsPre-clinical
BCA101Bicara TherapeuticsPhase 1
AN4005Adlai NortyePreclinical
AN3025Adlai NortyePreclinical